Metyrosine (metyrosine)
Pheochromocytoma treatment agents Oral Capsule
Last reviewed · Source: First Databank (FDB) drug data
Overview
Metyrosine is an inhibitor of catecholamine synthesis.
USES: This medication is used to treat high blood pressure in people with a certain adrenal gland tumor (pheochromocytoma). Metyrosine is used to prevent high blood pressure before and immediately after surgery to remove the tumor. It is also used long-term in people who cannot have the surgery.
It is not used for other kinds of high blood pressure. Metyrosine prevents the tumor from making certain natural substances (catecholamines) that raise the blood pressure and make the heart beat faster. Lowering the amount of catecholamines lessens the risk of a very serious attack of high blood pressure (hypertensive crisis).
Generic name: metyrosine
Pronunciation: (me-TYE-roe-seen)
Drug class: Pheochromocytoma treatment agents
Therapeutic class: Cardiovascular Therapy Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Metyrosine
Indications
The following indications are listed for Metyrosine:
- Pheochromocytoma Adjunct Therapy
Also known as: Adjunct Medication Therapy For Pheochromocytoma.
Dosing
No dosing information is available for this tab.
Metyrosine is administered orally.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Metyrosine 250 Mg Capsule | Maintenance | Take 1 capsule (250 mg) by oral route 4 times per day. |
| Drug label | Dosing type | Instructions |
|---|---|---|
| Metyrosine 250 Mg Capsule | Maintenance | Take 1 capsule (250 mg) by oral route 4 times per day. |
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
Moderate Interaction: Assess the risk to the patient and take action as needed.
Selected Antihypertensives And Vasodilators/Apomorphine
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Apomorphine causes dose-dependent decreases in blood pressure. Concurrent use with antihypertensive agents may result in additive effects on blood pressure.(1)
CLINICAL EFFECTS: Concurrent use of antihypertensives and apomorphine may result in orthostatic hypotension with or without dizziness, nausea, or syncope.(1)
PREDISPOSING FACTORS: The risk of orthostatic hypotension may be increased during dose escalation of apomorphine and in patients with renal or hepatic impairment.(1)
PATIENT MANAGEMENT: Patients receiving concurrent therapy should be monitored for hypotension. Counsel patients about the risk of orthostatic hypotension.(1)
DISCUSSION: Healthy volunteers who took sublingual nitroglycerin (0.4 mg) concomitantly with apomorphine experienced a mean largest decrease in supine systolic blood pressure (SBP) of 9.7 mm Hg and in supine diastolic blood pressure (DBP) of 9.3 mm Hg, and a mean largest decrease in standing SBP and DBP of 14.3 mm Hg and 13.5 mm Hg, respectively. The maximum decrease in SBP and DBP was 65 mm Hg and 43 mm Hg, respectively. When apomorphine was taken alone, the mean largest decrease in supine SBP and DBP was 6.1 mm Hg and 7.3 mm Hg, respectively, and in standing SBP and DBP was 6.7 mm Hg and 8.4 mm Hg, respectively.(1)
Selected Antihypertensives/Tizanidine
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Tizanidine is an alpha-2 agonist. Concurrent use with antihypertensive agents may result in additive effects on blood pressure.(1)
CLINICAL EFFECTS: Concurrent use of antihypertensives and tizanidine may result in hypotension.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Patients receiving concurrent therapy should be monitored for hypotension. The risk of hypotension may be decreased by careful titration of tizanidine dosages and monitoring for hypotension prior to dose advancement. Counsel patients about the risk of orthostatic hypotension.(1)
DISCUSSION: Severe hypotension has been reported following the addition of tizanidine to existing lisinopril therapy.(2-4)
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
- Crystalluria
- Extrapyramidal disease
- Hypotension
- Hypovolemia
- Depression
- Disease of liver
- Kidney disease with reduction in glomerular filtration rate (GFr)
- Urolithiasis
Adverse reactions
There is no enhanced messaging for this drug.
More Frequent
- Extrapyramidal disease
- Severe diarrhea
Rare or Very Rare
- Allergic dermatitis
- Anaphylaxis
- Anemia
- Angioedema
- Crystalluria
- Dyspnea
- Dysuria
- Eosinophilia
- Hallucinations
- Hematuria
- Parkinsonism
- Pharyngeal edema
- Thrombocytopenic disorder
- Thrombocytosis
- Trismus
- Urolithiasis
- Urticaria
More Frequent
- Drowsy
- Sedation
Less Frequent
- Acute abdominal pain
- Disorder of ejaculation
- Erectile dysfunction
- Galactorrhea not associated with childbirth
- Gynecomastia
- Headache disorder
- Nasal congestion
- Nausea
- Vomiting
- Xerostomia
Rare or Very Rare
- Acute cognitive impairment
- Depression
- Peripheral edema
- Skin rash
- Symptoms of anxiety
Precautions
No enhanced messaging available.
No enhanced messaging available.
Animal reproduction studies using metyrosine have not been performed to date. It is not known whether metyrosine can cause fetal harm when administered to pregnant women. There are no adequate and controlled studies to date using metyrosine in pregnant women. Metyrosine should be used during pregnancy only when clearly needed.
Since it is not known whether metyrosine is distributed into milk, the drug should be used with caution in nursing women.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Pheochromocytoma adjunct therapy | ||
| C74.1 | ICD10CM | Malignant neoplasm of medulla of adrenal gland |
| C74.10 | ICD10CM | Malignant neoplasm of medulla of unspecified adrenal gland |
| C74.11 | ICD10CM | Malignant neoplasm of medulla of right adrenal gland |
| C74.12 | ICD10CM | Malignant neoplasm of medulla of left adrenal gland |
| D35.0 | ICD10CM | Benign neoplasm of adrenal gland |
| D35.00 | ICD10CM | Benign neoplasm of unspecified adrenal gland |
| D35.01 | ICD10CM | Benign neoplasm of right adrenal gland |
| D35.02 | ICD10CM | Benign neoplasm of left adrenal gland |
| E31.22 | ICD10CM | Multiple endocrine neoplasia [MEn] type IIA |
| E31.23 | ICD10CM | Multiple endocrine neoplasia [MEn] type IIB |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.